A Chi­nese I/O biotech look­ing to turn around an old No­var­tis pro­gram gets a new fundraise af­ter launch­ing PhI­II study

Close to a year af­ter pulling in its last pri­vate fundraise, Chi­nese im­muno-on­col­o­gy biotech Ad­lai Nortye is back with an­oth­er nine-fig­ure round. And it comes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER